Evidence map›Paper›PMID 39835000›Full record

ArticleCureus2024

Challenges in the Management of Severe Serotonin Syndrome: A Case Report.

Pegah Yakhchalian, Kimia Mondegari, Rahi Reza Daneshvar

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pegah YakhchalianPsychiatry and Behavioral Sciences, Kaweah Delta Health Care District, Visalia, USA.
Kimia MondegariPsychiatry and Behavioral Sciences, Kaweah Delta Health Care District, Visalia, USA.
Rahi Reza DaneshvarPsychiatry and Behavioral Sciences, Kaweah Delta Health Care District, Visalia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonin syndrome (SS) is a potentially life-threatening condition that can result from excessive serotonergic activity, often due to SSRIs, formally known as selective serotonin reuptake inhibitors. The syndrome and its effects are often secondary to drug-drug interactions or dose-related. This case highlights a 47-year-old female who presents with a history of major depressive disorder, generalized anxiety disorder, and severe alcohol use disorder. She was brought to the Emergency Department after attempting suicide by ingesting an inordinate amount of bupropion (Wellbutrin). Although bupropion is not a direct serotonergic reuptake inhibitor, its inhibition of the CYP2D6 pathway has the potential to elevate the levels of alternative serotonergic agents, potentially leading to SS. The patient's symptoms were inclusive of autonomic instability and clonus, which are consistent with this syndrome, and which necessitated the discontinuation of all serotonergic medications, in addition to the initiation of supportive care. Management included benzodiazepines, guanfacine, and gabapentin to mitigate the glutamatergic activity SS can induce. This case emphasizes the need to closely monitor those prescribed this class of medications, while concomitantly incorporating interdisciplinary collaborative management for those afflicted with SS.

Indexed as

bupropion and serotonin syndromebupropion overdosemedication overdoseserotonin syndrome and autonomic instabilityserotonin syndrome management

Identifiers

PMID39835000
PMCPMC11743501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.